Novo Nordisk experimental drug CagriSema outperforms Wegovy in latest clinical trial
Novo Nordisk reports that its experimental drug CagriSema achieved greater weight loss and blood sugar reduction than Wegovy in a late-stage clinical trial.
Insights:
Novo Nordisk A/S announced on February 2, 2026, that its experimental drug CagriSema reduced blood sugar levels and body weight more than the existing drug Wegovy in a late-stage trial of patients with type 2 diabetes. According to information reported by Reuters on February 2, 2026, the trial demonstrated superior clinical outcomes compared to the current blockbuster therapy. The results are significant as they quantify the enhanced efficacy of the next-generation candidate in a direct comparison with established treatments.
